Free Trial
→ The SpaceX filing is public. The window is closing. (From Behind the Markets) (Ad)tc pixel
NASDAQ:FEED

Nanovibronix 5/18/2026 Earnings Report

Nanovibronix logo
$1.01 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$1.01 +0.00 (+0.20%)
As of 05/22/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Nanovibronix EPS Results

Actual EPS
-$6.88
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nanovibronix Revenue Results

Actual Revenue
$0.65 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nanovibronix Announcement Details

Quarter
Date
5/18/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Nanovibronix Earnings Headlines

ENvue Medical to Showcase ENvue™ Navigation Platform at AACN NTI 2026
May 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/19/3297586/0/en/envue-medical-to-showcase-envue-navigation-platform-at-aacn-nti-2026.html
Financial Review: Nanovibronix (NASDAQ:FEED) and MiniMed Group (NASDAQ:MMED)
May 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30785270
No. You’re not imagining it…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel
May 26 at 1:00 AM  |  Porter & Company (Ad)
ENvue Medical Secures Three-Year Contract Renewal at 12-Hospital U.S. Health Network as the ENvue™ Navigation Platform Becomes Standard of Care
May 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/12/3292861/0/en/envue-medical-secures-three-year-contract-renewal-at-12-hospital-u-s-health-network-as-the-envue-navigation-platform-becomes-standard-of-care.html
ENvue Medical Adds to Intellectual Property Portfolio by Securing USPTO Notice of Allowance for Ultrasound-Enhanced Cannabinoid Drug Delivery Technology
May 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/08/3291136/0/en/envue-medical-adds-to-intellectual-property-portfolio-by-securing-uspto-notice-of-allowance-for-ultrasound-enhanced-cannabinoid-drug-delivery-technology.html
ENvue Medical Secures Three-Year Purchasing Agreement Renewal with the Group Purchasing Organization (GPO) for One of the Largest Health Systems in the U.S. Operating Over 90 Hospitals
May 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3289978/0/en/envue-medical-secures-three-year-purchasing-agreement-renewal-with-the-group-purchasing-organization-gpo-for-one-of-the-largest-health-systems-in-the-u-s-operating-over-90-hospital.html
See More Nanovibronix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nanovibronix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nanovibronix and other key companies, straight to your email.

About Nanovibronix

Nanovibronix (NASDAQ:FEED) (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company's product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies. Its offerings are intended to be user‑friendly, portable and suitable for repeated application, which supports adoption in ambulatory care and self‑care environments. Nanovibronix emphasizes clinical research and device development to validate therapeutic effects and to support regulatory and reimbursement discussions in the markets it serves.

As a publicly traded entity on the NASDAQ exchange under the ticker FEED, Nanovibronix engages in the full product lifecycle from research and development through manufacturing, regulatory engagement and distribution. The company has historically sought to expand market access through clinical collaborations, distribution partnerships and targeted commercialization initiatives. Detailed, current information about specific products, regulatory clearances, market geographies or executive leadership was not available in the material used to prepare this summary.

View Nanovibronix Profile
Earnings Tools